Vimarsana
Biggest News Aggregation in the World

Page 9 - Recommendation Statement News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Recommendation Statement. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Recommendation Statement Today - Breaking & Trending Today

Wyndham Board Unanimously Recommends Wyndham Shareholders NOT Tender Shares - Vimarsana News

Wyndham Board Unanimously Recommends Wyndham Shareholders NOT Tender Shares

Article - Wyndham Board Unanimously Recommends Wyndham Shareholders NOT Tender Shares - Wyndham Board Believes the Company Can Deliver Long-Term Shareholder Value in Excess of the Current $85 Per Share in Cash and Stock Offered by Choice

Wyndham Confirms Receipt and Review of Unsolicited Exchange Offer from Choice - Vimarsana News

Wyndham Confirms Receipt and Review of Unsolicited Exchange Offer from Choice

Wyndham Hotels & Resorts (NYSE: WH) (“Wyndham” or the “Company”), the world’s largest hotel franchising company with approximately 9,100 hotels spanning more than 95 countries, today confirmed that Choice Hotels International, Inc. (NYSE: CHH) (“Choice”), has commenced an unsolicited exchange offer to acquire all outstanding shares of Wyndham common stock. The offer proposed by Choice appears unchanged from the terms outlined in a letter to Wyndham dated November 14, 2023 and is currently valued at approximately $86 per share.

Rain Oncology Enters into Agreement to be Acquired by Pathos AI for $1.16 in Cash per Share Plus Contingent Value Rights - Vimarsana News

Rain Oncology Enters into Agreement to be Acquired by Pathos AI for $1.16 in Cash per Share Plus Contingent Value Rights

NEWARK, Calif., Dec. 13, 2023 -- Rain Oncology Inc. , today announced it has entered into a definitive merger agreement whereby Pathos AI, Inc. will acquire Rain for $1.16 in cash per share plus...

AstraZeneca to Acquire Icosavax, Including Potential First-in-class RSV and hMPV Combination Vaccine With Positive Phase II Data - Vimarsana News

AstraZeneca to Acquire Icosavax, Including Potential First-in-class RSV and hMPV Combination Vaccine With Positive Phase II Data

Building on expertise in RSV prevention, acquisition will accelerate ambition to deliver portfolio of protective interventions to address high unmet needs in infectious diseases ...

AstraZeneca : to acquire Icosavax, including potential first-in-class RSV and hMPV combination vaccine with positive Phase II data - Form 6-K -December 12, 2023 at 06:30 am EST - Vimarsana News

AstraZeneca : to acquire Icosavax, including potential first-in-class RSV and hMPV combination vaccine with positive Phase II data - Form 6-K -December 12, 2023 at 06:30 am EST

A4665w FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or...